title: Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults.
abstract: OBJECTIVE
  To improve the long-term event-free survival of patients with Ewing's family of tumors (EFTs) using high-dose, short-term chemotherapy.
  
  
  METHODS
  P6 was a prospective study of previously untreated patients with newly diagnosed EFTs. Patients received seven cycles of chemotherapy. Cycles 1, 2, 3, and 6 consisted of cyclophosphamide 2,100 mg/m2/d on days 1 and 2, and a 72-hour continuous infusion of doxorubicin 75 mg/m2 and vincristine 2 mg/m2 starting day 1. Cycles 4, 5, and 7 consisted of 5 consecutive days of ifosfamide 1,800 mg/m2/d and etoposide 100 mg/m2/d.
  
  
  RESULTS
  Sixty-eight patients were enrolled from 1991 to 2001 (median age, 18.7 years; range, 3.7 to 39.9 years). At diagnosis, 44 patients had local-regional disease, and 24 had distant metastases. The 4-year event-free survival (EFS) rate for patients with local-regional disease is 82%; overall survival (OS) is 89%. The 4-year EFS rate for patients with distant metastases is 12%; the OS rate is 17.8%. All events occurred within 51 months of diagnosis. Four patients with distant metastases had progressive disease during therapy, and no patient with local-regional disease experienced disease progression during therapy.
  
  
  CONCLUSIONS
  Sustained EFS and OS can be achieved with intensive chemotherapy in children and young adults with local-regional EFTs. This therapy is relatively ineffective in the treatment of metastatic EFTs.
authors.affiliation: Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, PO Box 139, 1275 York Ave, New York, NY 10021,USA. meyersp@mskcc.org
authors.forename: E Anders
authors.initials: EA
authors.lastname: Kolb
authors.forename: Brian H
authors.initials: BH
authors.lastname: Kushner
authors.forename: Richard
authors.initials: R
authors.lastname: Gorlick
authors.forename: Caroline
authors.initials: C
authors.lastname: Laverdiere
authors.forename: John H
authors.initials: JH
authors.lastname: Healey
authors.forename: Michael P
authors.initials: MP
authors.lastname: LaQuaglia
authors.forename: Andrew G
authors.initials: AG
authors.lastname: Huvos
authors.forename: Jing
authors.initials: J
authors.lastname: Qin
authors.forename: Ha Thanh
authors.initials: HT
authors.lastname: Vu
authors.forename: Leonard
authors.initials: L
authors.lastname: Wexler
authors.forename: Suzanne
authors.initials: S
authors.lastname: Wolden
authors.forename: Paul A
authors.initials: PA
authors.lastname: Meyers
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage; D018450:Disease Progression; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008297:Male; D011446:Prospective Studies; D012008:Recurrence; D012074:Remission Induction; D012512:Sarcoma, Ewing / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D007069:Ifosfamide